2630 — Vigonvita Life Sciences Co Income Statement
0.000.00%
Last trade - 00:00- HK$13.68bn
- HK$14.42bn
- CNY102.10m
Annual income statement for Vigonvita Life Sciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 200 | 11.8 | 102 |
| Cost of Revenue | |||
| Gross Profit | 194 | 3.49 | 80.7 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 186 | 213 | 446 |
| Operating Profit | 13.6 | -201 | -344 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | 6.43 | -218 | -357 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 6.43 | -218 | -357 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | 12.1 | -211 | -356 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 12.1 | -211 | -356 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0.072 | -1.22 | -2.03 |